95901-60-3Relevant academic research and scientific papers
Potent and Specific Inhibition of NTCP-Mediated HBV/HDV Infection and Substrate Transporting by a Novel, Oral-Available Cyclosporine A Analogue
Liu, Yang,Ruan, Hanying,Li, Ying,Sun, Guoliang,Liu, Xiao,He, Wenhui,Mao, Fengfeng,He, Miaomiao,Yan, Liwei,Zhong, Guocai,Yan, Huan,Li, Wenhui,Zhang, Zhiyuan
supporting information, p. 543 - 565 (2021/01/13)
Analogues of the natural product cyclosporine A (CsA) were developed and assessed as antivirals against infection of hepatitis B virus (HBV) and its satellite hepatitis D virus (HDV). An analogue termed 27A exhibits potent inhibition of HBV/HDV infection by specifically blocking viral engagement to its cellular receptor NTCP, while it lacks immunosuppressive activity found in natural CsA. Intraperitoneal injection or oral intake of 27A protects HDV-susceptible mouse model from HDV infection. 27A serves as a promising lead for the development of novel anti-HDV/HBV agents.
NTCP INHIBITORS
-
Paragraph 0252, (2019/11/04)
Provided are cyclosporin A analogues that are NTCP inhibitors and useful for treating HBV and/or HDV infection (s), hepatoprotection and amelioration of hypercholesterolemia, diabetes and inhibiting cancer.
4-oxo-benzopyran carboxylic acids
-
, (2008/06/13)
Compounds of the Formula I: STR1 and pharmaceutically acceptable salts thereof are leukotriene antagonists. These compounds inhibit SRS-A and leukotriene synthesis and are antagonists of SRS-A and are thus useful in the treatment of asthma, allergic disorders, inflammation, skin diseases and certain cardiovascular disorders.
